GlassScriptPhysician profile
Juan M Velez
NPI 1497822902
$1,596.94
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,433 · 2020: $144 · 2022: $20.14.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.04 | 2019-2022 | |
| Intuitive Surgical, INC. | $564.39 | 2019 | |
| Allergan, INC. | $55.92 | 2019 | |
| Therapeuticsmd, INC. | $49.49 | 2019 | |
| Minerva Surgical, INC | $46.90 | 2019 | |
| Amag Pharmaceuticals, INC. | $44.61 | 2019 | |
| Aesculap, INC. | $39.95 | 2019 | |
| Lupin INC. | $30.37 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.56 | 2019-2020 | |
| Duchesnay USA Incorporated | $21.01 | 2019 | |
| Hologic Sales and Service, LLC | $15.96 | 2019 | |
| Merck Sharp & Dohme LLC | $12.74 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Research and ownership
$2,281.20 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Velez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.